Trial Profile
A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 14 Weeks Treatment With LMF237 Bid to Placebo in Patients With Type 2 Diabetes Inadequately Controlled With Vildagliptin 50 mg Bid Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2016
Price :
$35
*
At a glance
- Drugs Vildagliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 19 Sep 2014 Primary endpoint has been met (Change from baseline in glycosylated hemoglobin (HbA1c) at 14 weeks), according to the results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 24 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.